Moreover, in the non-randomized prospective B-F1RST trial evaluating atezolizumab monotherapy in advanced NSCLC, a decrease in serum CRP over six weeks predicted PFS and OS benefits [75]. Here, CRP is linked to non-small cell lung carcinoma.